Cat Fan
Cats and stats
Since people seem to doubt the numbers on vaccine protection against Delta, I went back to the Lancet article.
Two things to note. 1) It was based on a test negative analysis, i.e. this is protection against all types of infection (symptomatic and non-symptomatic). 2) they used a model to fit to the entire population so it should be a reliable population estimate.
It's the Lancet not the daily mail, to get published it has to be peer reviewed by experts.
Considering the whole population cohort (rather than just hospital cases), the test-negative analysis to estimate vaccine effectiveness in preventing RT-PCR-confirmed SARS-CoV-2 infection showed that, compared to those unvaccinated, at least 14 days after the second dose, BNT162b2 (Pfizer–BioNTech vaccine) offered very good protection: 92% (95% CI 90–93) S gene-negative, 79% (75–82) S gene-positive. Protection associated with ChAdOx1 nCoV-19 (Oxford–AstraZeneca vaccine) was, however, substantial but reduced: 73% (95% CI 66–78) for S gene-negative cases versus 60% (53–66) for those S gene-positive (appendix p 6). These estimates were obtained from a generalised additive logistic model adjusting for age, temporal trend when the swab was taken, and number of previous tests using splines plus sex and deprivation.
Two things to note. 1) It was based on a test negative analysis, i.e. this is protection against all types of infection (symptomatic and non-symptomatic). 2) they used a model to fit to the entire population so it should be a reliable population estimate.
It's the Lancet not the daily mail, to get published it has to be peer reviewed by experts.
DEFINE_ME
www.thelancet.com
Considering the whole population cohort (rather than just hospital cases), the test-negative analysis to estimate vaccine effectiveness in preventing RT-PCR-confirmed SARS-CoV-2 infection showed that, compared to those unvaccinated, at least 14 days after the second dose, BNT162b2 (Pfizer–BioNTech vaccine) offered very good protection: 92% (95% CI 90–93) S gene-negative, 79% (75–82) S gene-positive. Protection associated with ChAdOx1 nCoV-19 (Oxford–AstraZeneca vaccine) was, however, substantial but reduced: 73% (95% CI 66–78) for S gene-negative cases versus 60% (53–66) for those S gene-positive (appendix p 6). These estimates were obtained from a generalised additive logistic model adjusting for age, temporal trend when the swab was taken, and number of previous tests using splines plus sex and deprivation.